Colin F Spraggs

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. doi request reprint Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors
    Colin F Spraggs
    Genetics, Quantitative Sciences, GlaxoSmithKline Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
    Pharmacogenomics 14:541-54. 2013
  2. doi request reprint Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes
    C F Spraggs
    Genetics Department, GlaxoSmithKline Research and Development, Stevenage, UK
    Clin Pharmacol Ther 91:647-52. 2012
  3. ncbi request reprint Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar
    Colin Spraggs
    Pharmacogenetics, GlaxoSmithKline Research and Development, Harlow, Essex, UK
    Pharmacogenet Genomics 17:1065-76. 2007
  4. doi request reprint HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer
    Colin F Spraggs
    GlaxoSmithKline Research and Development, Genetics Division, Medicines Development Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NF, United Kingdom
    J Clin Oncol 29:667-73. 2011
  5. doi request reprint Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes
    Chun Fang Xu
    GlaxoSmithKline Medicines Research Centre, Rm 1S101, Gunnels Wood Rd, Stevenage, Hertfordshire, UK
    J Clin Oncol 29:2557-64. 2011
  6. doi request reprint Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma
    Chun Fang Xu
    GlaxoSmithKline Research and Development, Genetics Division, Stevenage, UK
    J Hepatol 54:1237-43. 2011
  7. pmc A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk
    Paul J Newcombe
    Genetics Division, GlaxoSmithKline, Stevenage, United Kingdom
    Genet Epidemiol 36:71-83. 2012
  8. ncbi request reprint Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects
    Colin F Spraggs
    Genetics Research, GlaxoSmithKline Research and Development, Medicines Research Centre, Stevenage, UK
    Pharmacogenet Genomics 15:883-9. 2005

Collaborators

Detail Information

Publications8

  1. doi request reprint Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors
    Colin F Spraggs
    Genetics, Quantitative Sciences, GlaxoSmithKline Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
    Pharmacogenomics 14:541-54. 2013
    ..The data presented demonstrate the utility of genetic studies to investigate drug-induced liver injury and potentially support its management in patients...
  2. doi request reprint Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes
    C F Spraggs
    Genetics Department, GlaxoSmithKline Research and Development, Stevenage, UK
    Clin Pharmacol Ther 91:647-52. 2012
    ....
  3. ncbi request reprint Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar
    Colin Spraggs
    Pharmacogenetics, GlaxoSmithKline Research and Development, Harlow, Essex, UK
    Pharmacogenet Genomics 17:1065-76. 2007
    ....
  4. doi request reprint HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer
    Colin F Spraggs
    GlaxoSmithKline Research and Development, Genetics Division, Medicines Development Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NF, United Kingdom
    J Clin Oncol 29:667-73. 2011
    ..This study sought to identify gene variants associated with lapatinib-induced ALT elevation and hepatobiliary AEs...
  5. doi request reprint Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes
    Chun Fang Xu
    GlaxoSmithKline Medicines Research Centre, Rm 1S101, Gunnels Wood Rd, Stevenage, Hertfordshire, UK
    J Clin Oncol 29:2557-64. 2011
    ..We tested the hypothesis that this variability is partially dependent on germline genetic variants that may affect pazopanib exposure or angiogenesis pathways...
  6. doi request reprint Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma
    Chun Fang Xu
    GlaxoSmithKline Research and Development, Genetics Division, Stevenage, UK
    J Hepatol 54:1237-43. 2011
    ..However, transaminase elevations have commonly been observed. This 2-stage study sought to identify genetic determinants of alanine transaminase (ALT) elevations in pazopanib-treated white patients with RCC...
  7. pmc A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk
    Paul J Newcombe
    Genetics Division, GlaxoSmithKline, Stevenage, United Kingdom
    Genet Epidemiol 36:71-83. 2012
    ..The two methods that included external information performed best, but only marginally despite substantial differences in complexity...
  8. ncbi request reprint Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects
    Colin F Spraggs
    Genetics Research, GlaxoSmithKline Research and Development, Medicines Research Centre, Stevenage, UK
    Pharmacogenet Genomics 15:883-9. 2005
    ....